Introduction {#section1-1073858414530512}
============

Microglia are the myeloid resident cell population of the central nervous system (CNS) parenchyma. The first identification of microglial cells was simultaneously reported by F. Robertson ([@bibr121-1073858414530512]) and F. Nissl ([@bibr104-1073858414530512]), who named them as "Staebchenzellen" based on the rod-like shape of their nuclei, describing them as reactive neuroglia. These cells later received the name of "microglia" from Pio del Rio-Hortega, a Spanish scientist from Santiago Ramon y Cajal's school, differentiating them from the other glial cells and highlighting their potential to differentiate from ramified to amoeboid cells ([@bibr28-1073858414530512]; [@bibr29-1073858414530512]; [@bibr30-1073858414530512]). Microglial cells are active sensors of the disturbances in their microenvironment, capable of elaborating a diverse spectrum of responses to restore tissue homeostasis ([@bibr55-1073858414530512]; [@bibr78-1073858414530512]). In keeping with the long-lasting definition as "the macrophages of the brain" it is only recently that microglial cells have been shown to have many potentially important functions in the normal development, function, and repair of the CNS ([Fig. 1](#fig1-1073858414530512){ref-type="fig"}). The understanding of microglial origin and functions in health and disease is experiencing a revolution, and many aspects of their physiology are being redefined. For example, the textbook dogma that microglial cells are of mesodermal origin, derived from hematopoietic stem cells in the bone marrow, has recently been rebutted by experiments demonstrating that microglia are mainly derived from the yolk sac, colonizing the neuroepithelium in early embryogenesis ([@bibr44-1073858414530512]). Other ideas, like the use of the terms "resting" or "quiescent" to define the behavior of microglial cells in the healthy brain, are now obsolete, as it indicates a degree of inactivity that does not reflect the current in vivo observations showing that microglia use their motile processes to actively scan the microenvironment, and to interact with synapses and with oligodendrocyte-derived myelin ([@bibr26-1073858414530512]; [@bibr37-1073858414530512]; [@bibr75-1073858414530512]; [@bibr103-1073858414530512]; [@bibr105-1073858414530512]; [@bibr123-1073858414530512]; [@bibr144-1073858414530512]). The remarkable potential of microglia to react to almost any form of disturbance of CNS homeostasis, infection, acute or chronic injury has often been viewed as an on-off switch, namely, "microglial activation" but this does not reflect the functional plasticity of these cells. The long-held assumption that microglial activation was detrimental and neurotoxic has dominated the scientific literature for many decades, stigmatizing the potential contribution of these cells to CNS physiology. In many experimental paradigms, the detrimental contribution of microglia has been demonstrated, as well as a clear neuroprotective function in others ([@bibr119-1073858414530512]). The current literature has extensively reviewed this issue in the past, presenting microglial cells as "friend or foe" or as a "double-edged sword" trying to understand the determinants of the positive versus negative microglial contributions to brain pathology, with the goal of minimizing the harmful and favoring the beneficial ([@bibr23-1073858414530512]; [@bibr116-1073858414530512]). However, capturing or promoting the beneficial effects alone is unlikely to be straightforward since the responses of microglia, like other tissue macrophages, are not linear, compartmentalized, or binary, but represent a highly plastic multifaceted response, finely tuned by the nature of the stimulus, the molecular repertoire that is engaged, and the prior state of the cell ([@bibr48-1073858414530512]; [@bibr119-1073858414530512]). This complex nature becomes particularly difficult to understand when taking into account the status of the immune-privilege of the brain that defines and tightly controls innate and acquired immune responses, but also their responses to the influence of pathological processes from peripheral organs ([@bibr113-1073858414530512]).

![Functional states of microglia in the healthy brain. The population of microglial cells is maintained by self-renewal, without the contribution of bone-marrow-derived progenitors. Surveillant microglial cells constantly scan the brain microenvironment, in order to detect minor perturbations of CNS homeostasis. Surveillant microglia can, for example, detect the presence of neurotoxic substances or inflammatory mediators from the systemic circulation, being in close communication with the blood-brain barrier (systemic sensing microglia). Phagocytic microglia can detect and quickly remove damaged or dying neurons, preventing the damage to neighboring cells and helping maintain the high turnover of specific cell populations (i.e., neural precursor cells). The phagocytic capacity of microglia is particularly important in development (pruning microglia), when they can contribute to the removal of supernumerary synapses in certain neuronal pathways. Moreover, it has been suggested that microglia can have a direct or indirect modulatory role at the synapse, influencing neuronal activity (neuromodulatory microglia).](10.1177_1073858414530512-fig1){#fig1-1073858414530512}

We suggest that it will be useful to describe the activity of microglial cells in diverse conditions, reacting to diverse stimuli, as functional states defined by specific functions, rather than limited molecular profiles or morphological criteria ([Fig. 1](#fig1-1073858414530512){ref-type="fig"}). In this review, we provide support to this approach by describing currently data available from the recent investigation of microglial functions in the CNS, assuming that the list of microglial functions will increase in diversity and complexity in the following years.

Microglial Functional States in the Healthy and Diseased Brain {#section2-1073858414530512}
==============================================================

Where Do Microglial Cells Come From? Migrating and Proliferating Microglia {#section3-1073858414530512}
--------------------------------------------------------------------------

The population of microglial cells in the adult murine CNS accounts for 5% to 12% of the total number of glial cells, depending on the region analyzed ([@bibr81-1073858414530512]). In humans, the microglial population accounts for 0.5% to 16.6% of the total of cells in the brain, showing similar regional variability as that of rodents ([@bibr94-1073858414530512]). Microglia in the human brain show higher densities in the white matter than in the grey matter, in contrast to rodents ([@bibr94-1073858414530512]). But, where do these cells come from and how they maintain the resident microglial population? Although a clear answer to the origin of microglia is getting much closer some questions remain.

Starting from pioneering studies from Del Rio-Hortega, it was assumed for decades that the adult microglial population originated from embryonic and perinatal waves of hematopoiesis and infiltration of circulating blood monocytes, followed by microglial differentiation (for review, see [@bibr45-1073858414530512]). Macrophage-like cells were reported in the brain parenchyma from early development (E12-16), as F4/80^+^ cells with amoeboid morphology ([@bibr98-1073858414530512]; [@bibr111-1073858414530512]; [@bibr146-1073858414530512]). Interestingly, several studies reported the presence of amoeboid cells expressing macrophage/microglia markers in the primitive developing brain (E8.5/E9.0), suggesting the idea of an early development and a yolk sac origin of the resident microglial population ([@bibr5-1073858414530512]; [@bibr18-1073858414530512]; [@bibr95-1073858414530512]). The definitive evidence supporting the yolk sac as origin of microglial cells was reported by Ginhoux and coworkers, and also highlighted the dependence of this developmental system on blood circulation, which is not required for the establishment of other tissue macrophage populations ([@bibr44-1073858414530512]). Moreover, the idea that microglia and other tissue macrophages constitute independent cell lineages is supported by recent studies highlighting the differences between macrophages derived from yolk sac and definitive hematopoiesis, the latter being dependent on the transcription factor Myb ([@bibr125-1073858414530512]).

The microglial population acquires its definitive composition, in terms of numbers and phenotype, soon after birth. A wave of microglial proliferation has been reported at early postnatal stages, but it is unclear if this could account for the increase in numbers of microglial cells, or rather suggesting the possible contribution of blood-derived monocytes ([@bibr5-1073858414530512]; [@bibr139-1073858414530512]). Although the postnatal infiltration of circulating monocytes and further differentiation to microglia has been described under certain experimental conditions, populating the corpus callosum ([@bibr85-1073858414530512]), or repopulating the whole microglial population ([@bibr8-1073858414530512]), further quantitative data are missing in the literature, a key to understand the final composition of the microglial population. Recent experiments using transgenic tagging of E7.25- versus E8.5-derived cells provided robust support to the idea that the microglial population is derived almost exclusively from the yolk sac, excluding the contribution of blood-derived monocytes ([@bibr44-1073858414530512]; [@bibr76-1073858414530512]; [@bibr125-1073858414530512]). The selective nature of the blood-brain barrier (BBB) could support this exclusive behavior, as complementary studies have defined that the rodent BBB is established at E13.5, before the release of monocytes into circulation and after the invasion of yolk sac-derived cells ([@bibr25-1073858414530512]).

The picture of the origin and maintenance of the human microglial population is not as clear as in rodents. Microglial cells have been described in the brain from the 3rd gestational week, appearing in the spinal cord at the 9th week, completing the colonization of the embryonic CNS at around 22 weeks ([@bibr68-1073858414530512]; [@bibr120-1073858414530512]). Microglial cells with ramified morphology can be only observed closer to term, around the 35th week ([@bibr34-1073858414530512]). Although these studies suggest very early waves of colonization of the CNS by yolk sac--derived hematopoietic precursors, preceding the onset of bone-marrow hematopoiesis, and are in accord with data arising from rodents, the exact dynamics of the human adult microglial population is still to be elucidated.

The recent redefinition of the microglial origin suggests an idea: the microglia population must be maintained by self-renewal of proliferating resident cells ([Figs. 1](#fig1-1073858414530512){ref-type="fig"} and [2](#fig2-1073858414530512){ref-type="fig"}). The relative contribution of bone-marrow-derived cells (BMCs) to the pool of perivascular macrophages (PVMs), meningeal macrophages (MMs), or parenchymal microglia in health and disease is a matter of intense debate ([Fig. 2](#fig2-1073858414530512){ref-type="fig"}). As discussed above, microglia originate from the yolk-sac and function largely independently of BMCs in the healthy brain ([@bibr44-1073858414530512]), pointing to in situ microglial proliferation as the mechanism regulating the population turnover, with little or no contribution from circulating progenitors ([@bibr82-1073858414530512]; [@bibr118-1073858414530512]). However, limited evidence is available in the literature defining the exact rates and regulation of microglial turnover in the healthy brain. Seminal work from Lawson and others ([@bibr82-1073858414530512]), using H^3^ thymidine combined with immunohistochemistry for F4/80, demonstrated that microglia proliferate in the healthy brain, but more slowly that other tissue macrophages: 0.05% of the microglia is proliferating at a given time, 20 times less than the lowest labeling index for any other resident macrophage population studied. However, these figures need to be reevaluated using more reliable detections methods to avoid underestimating the numbers of proliferating microglia. Moreover, we do not have precise information about the mechanisms/pathways regulating microglial proliferation in the steady state, or its counterpart microglial apoptosis, necessary to maintain a balanced population. Undoubtedly, the knowledge about microglial origin has expanded dramatically in the last years but there is still much to be done to reach a full understanding of microglial dynamics.

![Dynamics and functions of microglia in chronic neurodegenerative diseases. (**A**) In the normal brain, the microglial population has a surveillant phenotype, maintaining homeostasis. The microglia population is maintained by self-renewal, while the perivascular macrophages can be renewed by bone-marrow-derived progenitors. In Alzheimer's disease (AD) microglia proliferate and accumulate around plaques of amyloid β (Aβ), participating in the attempted removal of the misfolded protein. Perivascular macrophages have a more efficient phagocytic activity than microglial cells in AD. In AD, the microglial population is increased without a contribution from bone-marrow-derived cells. Microglia are expanded and activated during the course of amyotrophic lateral sclerosis (ALS), without a contribution from circulating progenitors. In prion disease, the microglial population is expanded dramatically by local proliferation (**B**; BrdU^+^), being primed to give an exaggerated response to systemic inflammatory events. Little evidence is available about the expansion/renewal of the microglial population during Parkinson's or Huntington's disease, or the dominant inflammatory phenotype. In general, the microglial population does not generate a uniform response and a diverse inflammatory prolife can coexist during disease (**C**; CD11c^+^ vs. CD11c^−^ microglia). For all the neurodegenerative diseases considered, little evidence is available about the possible contribution of perivascular macrophages (**D**; CD163^+^ CCR2^+^) to the expansion/renewal of the microglial population (**D**; CD163^−^ CCR2^−^), although both populations have different activation and proliferation patterns. (**B**-**D**) Representative examples evidenced in prion disease, detecting microglial cells by the transgenic expression of EGFP under the c-fms promoter.](10.1177_1073858414530512-fig2){#fig2-1073858414530512}

The understanding of the microglial population dynamics is yet more complex when studying the diseased brain. Recent studies support the idea that there is a minor or even absent contribution of BMCs to the microglial population in mouse models of Alzheimer's disease (AD) ([@bibr92-1073858414530512]), motor neuron disease and axotomy ([@bibr2-1073858414530512]), prion disease ([@bibr46-1073858414530512], [@bibr47-1073858414530512]), and stroke ([@bibr83-1073858414530512]) ([Fig. 2](#fig2-1073858414530512){ref-type="fig"}). In other diseases, like multiple sclerosis (MS), the evidence using genetic labeling of the different populations shows that expansion of the microglia/macrophage population is the result of a combination of both microglial proliferation and infiltration of circulating monocytes ([@bibr1-1073858414530512]).

A useful example to illustrate the shift in thinking about microglial cell dynamics is in the study of AD. Although local proliferation was assumed to be responsible for the consistently documented expansion of the microglial population observed in AD, mainly accumulating around plaques ([@bibr14-1073858414530512]; [@bibr41-1073858414530512]), direct evidence of proliferating microglial cells in animal models ([@bibr71-1073858414530512]) or human postmortem samples ([@bibr46-1073858414530512]) of AD was reported only recently. The detection of proliferating microglia in AD correlates with the up-regulation of the transcription factor PU.1 and the mitogens colony-stimulating-factor-1 (CSF1) and interleukin-34 (IL-34), key components of the pathway regulating microglial proliferation ([@bibr46-1073858414530512]). Another determinant of microglial proliferation, colony-stimulating factor 1 receptor (CSF1R), has also been found to be up-regulated in microglial cells during AD, indicating a prominent activity of this pathway ([@bibr4-1073858414530512]). These findings compare well with evidence reported in experimental models of prion disease, a paradigmatic chronic neurodegenerative disease that progress with a 10-fold expansion of the microglial population. Microglial proliferation in prion disease is maintained by the activity of the CSF1R signaling pathway, and specific antagonism of the receptor, using either blocking antibodies or the selective CSF1R inhibitor GW2580, highlights the detrimental contribution of microglial cells to the disease ([@bibr46-1073858414530512]). A reduction in the numbers of proliferating microglia, by specifically inhibiting CSF1R, delayed the onset of behavioral deficits and extended the time to terminal disease. The reported similar activity of the CSF1R pathway in experimental models of AD and prion disease, human prion disease (variant Creutzfeldt-Jakob disease; vCJD) and human AD, suggests common pathways controlling microglial proliferation and activation in chronic neurodegeneration ([@bibr46-1073858414530512]) ([Fig. 2](#fig2-1073858414530512){ref-type="fig"}). Furthermore, circulating progenitors do not contribute to the microglial population in prion disease, while they define the expansion of the PVMs population ([@bibr47-1073858414530512]). These studies pinpoint the importance of the control of microglial proliferation during neurodegeneration, offering new avenues for the regulation of the innate immune response in the brain. The analysis of the experimental models of prion disease offers an attractive perspective for the future, as they exhibit the main pathological features observed in many human neurodegenerative conditions (prion disease, AD, Parkinson's disease \[PD\]): protein misfolding, synaptic dysfunction, neurodegeneration, and an innate inflammatory reaction ([@bibr119-1073858414530512]).

Targeting the expansion of the microglial population has been used as an experimental tool to dissect the contribution of microglial cells to brain disease ([Fig. 2](#fig2-1073858414530512){ref-type="fig"}). For example, a repopulation method with SOD-1-expressing BMCs in microglia-devoid PU.1^−/−^ mice was used to define a detrimental contribution of microglia to the progression of experimental amyloid lateral sclerosis (ALS) ([@bibr8-1073858414530512]). Approaches in which microglial proliferation has been blocked, either by the transgenic expression of thymidine kinase (TK) and "suicide" of proliferating CD11b^+^ cells ([@bibr50-1073858414530512]; [@bibr51-1073858414530512]), or by the administration of the nonspecific blocker of mitosis Ara-C ([@bibr6-1073858414530512]), indicated a neutral or beneficial role of microglia in AD or ALS. However, the methods used in these studies did not take into account the inherent technical limitations. First, the use of CD11b-TK mice leads to a massive and uncontrolled death of microglia in the context of a CNS with ongoing neurodegeneration ([@bibr50-1073858414530512]; [@bibr51-1073858414530512]): this is not a "physiologically silent" way to address the contribution of microglial cells. Additionally, the activation of the TK transgene in CD11b-TK mice is achieved by administration of ganciclovir: this agent was recently identified to have a potent antiproliferative impact on microglia during brain pathology ([@bibr32-1073858414530512]). Second, the use of Ara-C causes a shift in the activation phenotype of microglia toward a detrimental pro-inflammatory profile, independent from its effects on cell proliferation ([@bibr46-1073858414530512]), probably explaining its detrimental effects on a model of ALS ([@bibr6-1073858414530512]). Other alternative approaches have studied the impact of increasing the proliferative activity of microglia with recombinant CSF1. These studies also suggest a detrimental role for microglia in the pathophysiology of ALS ([@bibr49-1073858414530512]), although these experiments also affected the contribution from CSF1-responsive peripheral cells. As previously suggested, the use of experimental strategies targeting the pathway(s) regulating microglial proliferation would provide a clearer readout of the overall contribution of microglia to the pathogenesis of diverse neurodegenerative conditions.

In a number of important neurodegenerative conditions the study of microglial population dynamics remains mostly unexplored. For example, PD is characterized by the presence of morphologically activated microglia ([Fig. 2](#fig2-1073858414530512){ref-type="fig"}), evidenced in human postmortem samples ([@bibr89-1073858414530512]), and by in vivo PET imaging, showing increased binding of the microglial-specific ligand PK-11195 without any correlation with the clinical symptoms ([@bibr43-1073858414530512]). Also, in Huntington's disease (HD), progressive morphological activation of microglia and increase in their number has been evidenced in human brain from early presymptomatic stages of the disease, suggestive of a causative role for these cells in the pathology ([@bibr122-1073858414530512]; [@bibr138-1073858414530512]). Binding studies of PK11195 to microglia using PET imaging in HD patients suggests that microglial activation correlates with the severity of the disease ([@bibr107-1073858414530512]), leading to the suggestion that they might provide a useful diagnostic tool to predict disease onset ([@bibr115-1073858414530512]). However, the contribution of BMCs infiltration versus microglia proliferation to the expansion of the PVMs, MMs, or parenchymal microglial population in PD or HD remains unexplored and is of importance to fully understand the innate immune response in these brain pathologies ([Fig. 2](#fig2-1073858414530512){ref-type="fig"}). Analyzing PVMs, MMs, and microglial proliferation under pathological conditions with widespread degeneration is critical for understanding how innate inflammation contributes to the onset and progression of the disease. Recent studies have highlighted the ability of PVMs to clear amyloid β (Aβ) in experimental models of AD ([@bibr92-1073858414530512]) and show the need for a better understanding of the differential contribution of BMCs, MMs, and PVMs for the expansion of the microglial population and providing a key link with systemic inflammatory events.

Surveillant Microglia {#section4-1073858414530512}
---------------------

The cytoarchitecture of the microglial population is regularly organized, forming a tightly controlled mosaic, independent of cell layers or blood vessels ([@bibr81-1073858414530512]). However, the microglial population shows remarkable anatomical diversity. Microglial cell density can vary across regions, representing a 12% of total cells in the substantia nigra or 5% of the corpus callosum of rodent brains ([@bibr81-1073858414530512]) or 0.3% of the total cells in the cerebellar grey matter and 16.9% in the medulla oblongata of human brains ([@bibr94-1073858414530512]). Microglial morphology is also diverse, with elongated and orientated cells in the white matter or amoeboid cells in the circumventricular organs, in contrast to the more abundant radially orientated arborized morphology ([@bibr81-1073858414530512]).

The application of live imaging techniques to the study of the brain provided dynamic details of the microglial population. In both mice and zebrafish, microglia constantly and rapidly scan the microenvironment with their processes, while keeping the soma in a fixed position ([@bibr26-1073858414530512]; [@bibr103-1073858414530512]; [@bibr144-1073858414530512]) ([Fig. 1](#fig1-1073858414530512){ref-type="fig"}). Contact between processes is avoided during the scanning of the parenchyma, maintaining the mosaic distribution and the cell size ([@bibr103-1073858414530512]). However, ageing has been shown to affect microglial stability, leading to a disruption of the mosaic organization, a decrease in the motility of microglial processes, and a remarkable increase in the motility of their somas ([@bibr56-1073858414530512]). Although the dynamic process of microglial surveillance of the brain parenchyma has been characterized in detail, we have less information about the elevated energy expenditure associated with actin polymerization ([@bibr60-1073858414530512]) and about the microglial mechanisms to control this inherently high metabolic rate.

The maintenance of the surveillant microglial phenotype is achieved by diverse soluble or membrane-bound factors with neuronal or non-neuronal origin ([@bibr55-1073858414530512]; [@bibr74-1073858414530512]). However, the regional heterogeneity of the brain (different neurotransmitter environment, myelin content, BBB properties, etc.) and the impact of systemic events on the microglial receptor signature must be translated into region and time-specific mechanisms of surveillance, which are not fully understood to date. Microglial dynamics can be stimulated by factors like ATP and other nucleotides ([@bibr26-1073858414530512]; [@bibr38-1073858414530512]) or reduced by factors including CX3CL1 ([@bibr84-1073858414530512]), with other well-know modulatory systems like CD200, CD47, or GABA still not fully understood ([@bibr74-1073858414530512]).

Pruning and Neuromodulatory Microglia {#section5-1073858414530512}
-------------------------------------

The initial phases of postnatal brain development are characterized by a process of remarkable plasticity involving neuronal and glial cell death, and synaptic pruning or remodeling. In an activity-dependent manner, extranumerary synapses are eliminated, while the remaining ones are strengthened to form the adult connectivity ([@bibr65-1073858414530512]; [@bibr72-1073858414530512]). The mechanism regulating the removal of synapses was elusive, but now microglial cells have been proposed as key executive players. The association of microglia with areas subjected to intense postnatal cell death and synaptic remodeling was evidenced for many years ([@bibr24-1073858414530512]; [@bibr36-1073858414530512]; [@bibr111-1073858414530512]). The involvement of microglia in the active elimination of extranumerary synapses was proposed in the context of the study of the developing retinogeniculate system, where a complement-dependent remodeling process leads to eye-specific segregation in the dorsal lateral geniculate nucleus ([@bibr135-1073858414530512]) ([Fig. 1](#fig1-1073858414530512){ref-type="fig"}). In this system, microglia were later found to engulf some synapses in a complement (C3)-dependent manner, directly shaping neuronal connectivity ([@bibr123-1073858414530512]). Additionally, the CX3CR1-CX3CL1 system has also been suggested to regulate synapse pruning by microglia, as deficiencies in CX3CR1 led to a reduction of microglial density, which is in turn associated with a modest and transient defect in developmental synaptic connectivity ([@bibr105-1073858414530512]). More recently, the CX3CR1-CX3CL1 system has been directly evidenced to determine functional brain connectivity and behavioral changes ([@bibr151-1073858414530512]). In addition to microglial pruning activity in the retinogeniculate system, astrocytes were recently found to also remove synapses, involving the MEGF10 and MERTK phagocytic pathways ([@bibr19-1073858414530512]). Although synaptic pruning seems associated with development of CNS circuitry, evidence at the ultrastructural level suggests a role of microglia in the reorganization of adult circuits following sensory loss ([@bibr143-1073858414530512]) or during ischemia ([@bibr144-1073858414530512]).

The precise role of microglia in the process known as "synaptic stripping", the separation of the presynaptic terminal from an injured postsynaptic neuron, is a matter of controversy ([@bibr112-1073858414530512]). There are important species differences in mouse and rat and the involvement of astrocytes has been overlooked in some studies ([@bibr150-1073858414530512]). The initial definition of synaptic stripping by microglial processes in the injured facial nerve ([@bibr12-1073858414530512]) was supported by findings in MeCP2-deficient mice, evidencing the impact of microglial-derived glutamate on the synaptic element ([@bibr86-1073858414530512]). Further evidence from live imaging supported a transient and rapid interaction or contact of microglial processes with axon terminals and dendritic spines, being modulated by neuronal activity ([@bibr144-1073858414530512]). In the disease context, the interaction of microglial processes with axon terminals has been shown altered in a model of ischemia, suggesting an active role of this interaction in the preservation of the synaptic connectivity ([@bibr144-1073858414530512]). However, in a prion disease model of chronic neurodegeneration, in which extensive synaptic degeneration occurs prior to death of the neuronal soma, the synapses degenerate and are enveloped by the spine postsynaptic density without the involvement of microglial cells ([@bibr132-1073858414530512]).

Although the microglial pruning has been described during postnatal development, it is still unclear how widely this mechanism is involved in earlier stages of development, during disease, and in pathologies with a component of synaptic degeneration. Without doubt this arena will attract significant attention in the next years and will provide valuable information to fully understand the link of the inflammatory response with neuronal degeneration.

Further to the pruning role of microglia, some evidence suggests a direct participation in the regulation of neuronal activity, in a quad-partite model together with astrocytes ([@bibr7-1073858414530512]; [@bibr124-1073858414530512]) ([Fig. 1](#fig1-1073858414530512){ref-type="fig"}). Microglial activation with LPS causes an increased production of ATP that signals to astrocytes to produce an increased excitatory postsynaptic current in hippocampal neurons ([@bibr106-1073858414530512]). This direct and intimate relationship with astrocytes and neurons is supported at the ultrastructural level, where microglial processes have been shown in contact with excitatory synaptic elements ([@bibr142-1073858414530512]). However, other electron microscopy studies show that only a small percentage, 3.5%, of synapses receive direct contact by a microglial process, questioning the overall impact or direct relevance of microglia on synaptic activity ([@bibr133-1073858414530512]).

Phagocytic Microglia {#section6-1073858414530512}
--------------------

The phagocytic activity of microglia is one of the features in common with their cellular cousin, the macrophage, and helps eliminate bacteria during infections, necrotic and apoptotic cells during development or disease ([@bibr127-1073858414530512]). Phagocytic microglia removes apoptotic debris in the developing and adult brain ([Fig. 1](#fig1-1073858414530512){ref-type="fig"}), keeping cell death silent and avoiding the deleterious secretion of pro-inflammatory cytokines and chemoatractants driving the migration of T cells; therefore, phagocytosis has a net beneficial effect ([@bibr17-1073858414530512]; [@bibr87-1073858414530512]). However, data arising firstly from in vitro studies ([@bibr100-1073858414530512]) and more recently from in vivo experiments ([@bibr42-1073858414530512]; [@bibr99-1073858414530512]) support the notion that microglia can actively remove endangered but potentially viable neurons, contributing to brain pathologies with a neuroinflammatory component. These ideas lead to the use of the term "phagoptosis" to define the selective attack and removal of damaged but viable neurons by microglia, resembling similar cell-cell interactions observed in peripheral organs ([@bibr15-1073858414530512]).

The study of the role of phagocytic microglia in the healthy brain is perhaps exemplified by the study of the hippocampal neurogenic niche ([@bibr127-1073858414530512]) ([Fig. 1](#fig1-1073858414530512){ref-type="fig"}). The neurogenic cascade at the hippocampal subgranular layer (SGL) leads to the generation of a population of early neural precursor cells (NPCs), which become finely selected by apoptosis, before completing the maturation to granule cells ([@bibr73-1073858414530512]; [@bibr93-1073858414530512]). In this niche, ramified phagocytic microglia rapidly and efficiently remove dying NPCs in a non-inflammatory fashion ([@bibr128-1073858414530512]). When challenged with LPS, NPCs undergo increased apoptosis ([@bibr128-1073858414530512]), although it is unclear if as a consequence of the indirect production of pro-inflammatory cytokines or direct phagoptosis.

In addition to the direct removal of dead/damaged/alive cells, phagocytic microglia can engulf and prune synapses ([@bibr123-1073858414530512]), clear axonal and myelin debris ([@bibr64-1073858414530512]; [@bibr102-1073858414530512]) or clear potentially toxic proteins such as amyloid beta (Aβ) ([@bibr127-1073858414530512]). In the case of AD, the plaque burden increases with age, in both mouse models and human patients, indicating the rather ineffective phagocytic activity of microglia. In other models of chronic neurodegeneration, like the prion disease model, microglia have limited abilities to remove misfolded prion protein (PrP^sc^) ([@bibr66-1073858414530512]). Aβ deposits have been shown to have a potent chemoattractant activity on microglia, although their removal by phagocytosis has not been clearly evidenced in vivo ([@bibr127-1073858414530512]). However, the removal of Aβ can be improved by further challenge of microglia with high doses of LPS ([@bibr58-1073858414530512]) or the induction of IL-1β ([@bibr126-1073858414530512]). Although a significant body of literature suggested that BMCs can play a leading role in the removal of Aβ, therefore complementing the poor phagocytic activity of microglia ([@bibr130-1073858414530512]; [@bibr129-1073858414530512]), more recent evidence from Prinz and colleagues support a differential contribution of perivascular macrophages and parenchymal microglia, not BMCs, to the clearance of Aβ ([@bibr92-1073858414530512]). In fact, the regulation of the phagocytic activity of microglia appears as a key genetic determinant of AD pathology. Recent studies link genetic variants of TREM2, a protein regulating the activation and phagocytic functions of myeloid cells, with the risk of developing AD ([@bibr54-1073858414530512]; [@bibr69-1073858414530512]). TREM2 has a balancing role between phagocytic and pro-inflammatory microglial activities and is expressed in microglia around plaques ([@bibr40-1073858414530512]). Similarly, dysregulation of the complement system in humans has been associated with AD ([@bibr80-1073858414530512]; [@bibr90-1073858414530512]). However, as discussed above, no clear consensus defines the overall role of microglial phagocytosis in the diseased brain.

These conflicting findings, supporting a beneficial or a detrimental contribution of phagocytic microglia, need to be investigated and validated in detail in diverse in vivo experimental paradigms, escaping from confounding in vitro systems, before considering the application of anti-phagocytosis neuroprotective therapies, for example. Moreover, the use of refined experimental approaches to directly study microglial phagocytosis ([@bibr128-1073858414530512]), rather than studying immunological markers such as CD68 (with still ill-defined functions in microglia), will shed light on the understanding of phagocytic microglia in health and disease.

Inflammatory Microglia {#section7-1073858414530512}
----------------------

Although the above-described functional states of microglia are significant contributions to our understanding the physiology of these cells, it is the inflammatory functions of microglia that dominate the scientific literature ([@bibr74-1073858414530512]; [@bibr119-1073858414530512]). In this section, we aim at providing some ideas, comparing the microglial inflammatory reaction in different pathologies without providing a comprehensive review of all the possible brain pathological states, which can be found in the literature ([@bibr55-1073858414530512]; [@bibr74-1073858414530512]; [@bibr119-1073858414530512]). But, before reviewing the inflammatory functions of microglia during brain pathology, it may be informative to pay attention to the inflammatory profile of microglial cells in the healthy brain. Recent analysis of the microglial transcriptome show a profile dominated by RNAs encoding proteins for sensing endogenous ligands and microbes collectively referred as the "microglial sensome" ([@bibr59-1073858414530512]). During ageing, microglia up-regulate the expression of microbe-recognition genes, together with genes involved in neuroprotection ([@bibr59-1073858414530512]). A detailed comparison of the transcriptomic profile of microglia has also recently provided evidence about a unique functional signature in microglia, dominated by the activity of TGF-β ([@bibr16-1073858414530512]). This microglial gene signature, common to murine and human cells, allows the specific differentiation of microglia, when compared with other myeloid or immune cells, resident brain cells (oligodendrocytes, astrocytes, and neurons), microglial cells lines, or recruited monocytes, highlighting the particularities of the microglial population ([@bibr16-1073858414530512]). Compared to other tissue macrophages, microglia in the healthy brain have a down-regulated expression of molecules like CD45, Fc receptors, or MHC class II ([@bibr113-1073858414530512]). The interaction of astrocytes and neurons with microglia provides a regulatory system to maintain the inflammatory pathways of microglia under control. Molecules like NGF or BNDF inhibit the expression of MHCII and its co-stimulatory molecules B7 and CD40 in microglia, respectively ([@bibr101-1073858414530512]; [@bibr148-1073858414530512]). Also, neurotransmitters like GABA can control the inflammatory functions of microglia ([@bibr114-1073858414530512]). Additionally, the role of cell--cell interactions in the control of the microglial inflammatory phenotype has been studied in depth. For example, neuronal signaling using the CD200-CD200R or Siglecs systems inhibits the inflammatory activation of microglia, through the use of ITIM motifs (immunoreceptor tyrosine-based inhibitory motif) ([@bibr10-1073858414530512]). When the control of these systems is lost, during neuronal degeneration for example, the inhibitory control is released from microglia, unleashing an inflammatory reaction ([@bibr9-1073858414530512]; [@bibr152-1073858414530512]). However, the idea that the microglial cell needs to be restrained is probably driven by the initial views of these cells as "the bad guys" and a more detailed reevaluation of these regulatory systems, together with novel ones, will inform about the maintenance of the brain homeostasis.

The inflammatory functions of microglia have special relevance for the understanding of the progression of neurodegenerative diseases. Despite a long-standing interest in the inflammatory response in AD, and the extensive research focused on understanding the role of microglia in this disease, the scientific community has failed to shed clear and uniform light into their contribution to the disease ([@bibr3-1073858414530512]; [@bibr57-1073858414530512]; [@bibr119-1073858414530512]). The neuropathology of AD shows a robust innate immune response characterized by the presence of activated microglia, with increased or de novo expression of diverse macrophage antigens ([@bibr3-1073858414530512]; [@bibr33-1073858414530512]), and at least in some cases production of inflammatory cytokines ([@bibr31-1073858414530512]; [@bibr35-1073858414530512]). The fact that NSAIDs (nonsteroidal anti-inflammatory drugs) protect from the onset or progression of AD ([@bibr63-1073858414530512]) suggests that inflammation is a causal component of the disease rather than simply a consequence of the neurodegeneration. The recent demonstration of several innate immune genes in genome-wide association studies (GWAS) of AD also implicates inflammation as causal in the disease ([@bibr110-1073858414530512]). Additionally, a growing body of evidence suggests that systemic inflammation may interact with the innate immune response in the brain to act as a "driver" of disease progression and exacerbate symptoms ([@bibr62-1073858414530512]; [@bibr61-1073858414530512]) ([Fig. 3](#fig3-1073858414530512){ref-type="fig"}). Studies in animal models show evidence of interactions between systemic inflammation and inflammation in the brain and importantly provide biologically plausible mechanisms for its contribution to the progression of neurodegeneration ([@bibr113-1073858414530512]). The impact of systemic inflammation means that any neuropathology studies on the inflammatory response in the AD brain must take into account systemic co-morbidities that may influence the microglia phenotype ([Fig. 3](#fig3-1073858414530512){ref-type="fig"}).

![Impact of systemic inflammation on the progression of chronic neurodegeneration: microglial priming. Schematic representation of the cross-talk of microglial cells with neurons and astrocytes in the healthy brain (**A**), during chronic neurodegeneration (**B**), and when chronic neurodegeneration is combined with a systemic inflammatory event (**C**). (**A**) In the healthy brain, surveillant microglia maintain the brain homeostasis and are renewed by local proliferation. Astrocytes and microglia communicate with neurons to support their function and survival, among other functions (see [Fig. 1](#fig1-1073858414530512){ref-type="fig"}). (**B**) In chronic neurodegeneration, microglia activate an inflammatory program and become primed. The microglial population is expanded mainly by local proliferation. Astrocytes lose control of the blood-brain barrier and inflammatory mediators and cells enter into the brain. Neurons undergo a progressive but limited damage. (**C**) When a systemic inflammatory event is combined with chronic neurodegeneration, primed microglia are further activated and damage endangered neurons, accelerating the pathology. The microglial population can be supplemented by bone-marrow-derived cells. Astrocytes become activated and further contribute to neuronal damage. (**A**-**C**) Microglial cells (red) exemplifying the different conditions are shown at the bottom. In **C**, primed microglial cells are shifted to a pro-inflammatory phenotype, expressing IL1β (green). The legend for the different cell types and phenotypes is provided at the bottom.](10.1177_1073858414530512-fig3){#fig3-1073858414530512}

The definition of the brain inflammatory profile in AD shows conflicting ideas in the literature, probably arising from the heterogeneity of the postmortem samples and the difficult application of the detection methods ([@bibr13-1073858414530512]). Some authors have associated AD with a pro-inflammatory phenotype, characterized by expression of IL-1β and complement proteins, with a direct association with Aβ plaques in human samples ([@bibr53-1073858414530512]; [@bibr52-1073858414530512]; [@bibr88-1073858414530512]). By contrast, other groups have reported the up-regulation of genes linked to an anti-inflammatory phenotype, arginase 1 or the transforming growth factor-β (TGF-β), in association with AD ([@bibr20-1073858414530512]; [@bibr147-1073858414530512]). The study of transgenic models of amyloidosis, modeling some aspects of AD, shows morphological activation of microglia that reproduce the deposition of Aβ ([@bibr70-1073858414530512]; [@bibr79-1073858414530512]; [@bibr109-1073858414530512]). However, the associated cytokine profile is by no means clear, as in the human AD brain the inflammatory response cannot be classified as strictly M1-like or M2-like ([@bibr137-1073858414530512]), with the changes in expression level compounded by the various detection methods (for review about research methods to study microglial biology, see [@bibr119-1073858414530512]).

Although the precise inflammatory phenotype of microglia in AD seems elusive, the link of AD with inflammation seems clear, as highlighted by a recent study on the gene signature of ageing and AD, using microarray technology ([@bibr21-1073858414530512]). These results support the notion of an activation of the innate inflammatory response in microglia as a prelude to the subsequent development of AD ([@bibr21-1073858414530512]). Furthermore, studies on incipient AD (iAD) postmortem samples show a strong correlation between genes associated with the microglial response and the progression into AD ([@bibr11-1073858414530512]). The concept of the interconnection of AD and the innate immune response is further supported by evidence from GWAS implicating genes involved in innate immunity ([@bibr80-1073858414530512]). These promising studies are opening new avenues into the understanding of the impact of the innate immune response in AD, while supporting the need for future exploration.

In PD, some studies suggest that microglia have a pro-inflammatory phenotype, which is potentially driving neuronal injury ([@bibr67-1073858414530512]; [@bibr96-1073858414530512]), although no mechanistic study has yet addressed microglial contribution to the disease progression in humans. The interpretation of the inflammatory response in PD is complicated by the fact that PD has a late onset and that most studies analyzed end-stage samples, representing a brain that has been suffering from the disease for many years. Ageing alone has an impact on the phenotype of microglia, and systemic comorbidities, which can influence the microglial physiology, have not been taken into account in the previous studies focusing on PD ([@bibr108-1073858414530512]). The clinical course of PD is often associated with other comorbidities, like chronic constipation or aspiration pneumonia, driving a peripheral inflammatory response that might impact the brain microglial responses and the progression of PD ([@bibr108-1073858414530512]) ([Fig. 3](#fig3-1073858414530512){ref-type="fig"}).

The understanding of the role of microglia in PD comes from the study of experimental animal models, although they fail to accurately reflect the neuropathology of PD as described in humans. PD is characterized by a slowly evolving degeneration of the substantia nigra (SN) dopaminergic neurons, an aspect not replicated in these models using either neurotoxic toxins or inflammatory challenges. The use of intracerebral neurotoxins, most commonly 6-hydroxydopamine (6OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), or rotenone, provides a rapid degeneration (within a few days) of the SN dopaminergic neurons. Microglial activation has been described in the 6OHDA and MPTP models of PD ([@bibr91-1073858414530512]; [@bibr145-1073858414530512]), although limited information is available regarding the inflammatory phenotype of these cells, in contrast to their morphological features, which have been described in detail. Studies modulating microglial activity with minocycline, an antibiotic having anti-inflammatory actions, provided contrasting, model-dependent results, about the contribution of innate inflammation to the acute neurodegeneration of dopaminergic neurons in the SN ([@bibr134-1073858414530512]; [@bibr149-1073858414530512]). Systemic inflammation, induced by administering IL-1β, was shown to impact the survival of dopaminergic neurons in the 6OHDA model, providing clear evidence of the influence of immune-to-brain communication on the progression of PD ([@bibr117-1073858414530512]). Additionally, the generation of transgenic mouse models of PD, based on the identification of genes linked with familial PD, also provides a promising approach to model chronic neurodegeneration ([@bibr27-1073858414530512]). For example, transgenic overexpression of α-synuclein, a protein linked genetically to PD, leads to microglial activation and production of TNF-α in the SN ([@bibr136-1073858414530512]), although little neuronal death is observed. Both transgenic and inflammatory models of PD can capture aspects of the disease, but fail to provide a comprehensive picture in which to address the roles of the innate immune response, in the context of a slowly evolving neurodegenerative condition. To summarize, the contribution of microglial cells to the onset or progression of PD is not yet established. Further research into the effect of systemic comorbidities ([Fig. 3](#fig3-1073858414530512){ref-type="fig"}) and in refining the experimental animal models will help understand the roles of the innate immune response in PD.

In HD, a progressive morphological activation of microglia and increase in their number has been evidenced in the brain from early pre-symptomatic stages, suggestive of a causative role for these cells in the disease ([@bibr122-1073858414530512]; [@bibr138-1073858414530512]). Microglial activation can be exacerbated by systemic LPS in a mouse model of HD, having no impact on the neurological symptoms ([@bibr39-1073858414530512]). A detrimental contribution of microglia in HD has been suggested, through complement-mediated neuronal damage, although supporting mechanistic evidence is limited ([@bibr131-1073858414530512]). Other in vitro studies have evidenced microglial proliferation and pro-inflammatory activation in HD, suggesting a reparative role in the removal of dysfunctional neurites at early and middle stages of the pathology ([@bibr77-1073858414530512]). The current evidence supports the idea that microglial cells are activated during HD, but the question of whether the innate immune response is a bystander consequence or whether they have a direct effect on the disease progression is still a matter of debate and needs further research ([@bibr97-1073858414530512]). Interestingly, recent reports highlight the direct effect of mutant Huntingtin on the activation of microglia, suggesting a cell-autonomous regulation of the innate immune response in HD ([@bibr22-1073858414530512]). The impact of systemic inflammatory events is clear during the progression of HD, as peripheral myeloid cells have been shown to produce altered levels of inflammatory cytokines ([@bibr140-1073858414530512]; [@bibr141-1073858414530512]).

In summary, the study of the inflammatory response of microglial cells during brain pathology needs to keep on focusing the interest of scientific community in the future. The use of cell- and expression-profiling techniques in animal models of disease and a more detailed and advanced use of postmortem human samples at earlier stages of disease will help understand the key inflammatory pathways defining the microglial function in brain disease and to develop promising immunomodulatory therapeutic strategies.

Concluding Remarks {#section8-1073858414530512}
==================

The study of the functional states of microglia, and their effects on the physiology of the brain, in health and disease, are only starting to be understood. The successful application of technical and experimental innovation to the study of microglia has unveiled functions previously undefined, opening new avenues of research. To better understand, and define, the roles of microglia in the brain, we propose the study of their functions: surveillant microglia, proliferating microglia, pruning/neuromodulatory microglia, phagocytic microglia, and inflammatory microglia, and then the molecular profiles that are associated with these functions. Following this approach we would understand what microglia "are doing" rather than what they express, which will significantly overlap in many of these states, providing more precise information about their roles in health and disease. With a more or better definition of new functions, the future of the study of microglia cells is a promising and exciting arena that will determine how we understand brain function in health and disease.
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